ACAN

Across TCGA pan-cancer cohorts, ACAN mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACAN data layer compared with 24 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ACAN mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ACAN expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where ACAN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.888	0.431	.001	17	view →
LSCC	OS	Median	II,III,IV	0.703	0.966	.005	14	view →
CCRCC	OS	Tertile	II,III,IV	0.930	0.704	.021	2	view →
GBM	OS	Tertile	All	0.947	0.673	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACAN–PDAC (DFS)

Open the PDAC breakdown →